- Home
- OCFC vs RCUS Comparison
OCFC vs RCUS Comparison
Compare OCFC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFC
- RCUS
- Stock Information
- Founded
- OCFC 1902
- RCUS 2015
- Country
- OCFC United States
- RCUS United States
- Employees
- OCFC N/A
- RCUS N/A
- Industry
- OCFC Major Banks
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- OCFC Finance
- RCUS Health Care
- Exchange
- OCFC Nasdaq
- RCUS Nasdaq
- Market Cap
- OCFC 861.7M
- RCUS 727.1M
- IPO Year
- OCFC 1996
- RCUS 2018
- Fundamental
- Price
- OCFC $16.50
- RCUS $8.41
- Analyst Decision
- OCFC Buy
- RCUS Strong Buy
- Analyst Count
- OCFC 4
- RCUS 10
- Target Price
- OCFC $21.75
- RCUS $27.63
- AVG Volume (30 Days)
- OCFC 331.8K
- RCUS 1.3M
- Earning Date
- OCFC 04-24-2025
- RCUS 05-06-2025
- Dividend Yield
- OCFC 4.84%
- RCUS N/A
- EPS Growth
- OCFC N/A
- RCUS N/A
- EPS
- OCFC 1.65
- RCUS N/A
- Revenue
- OCFC $375,233,000.00
- RCUS $258,000,000.00
- Revenue This Year
- OCFC N/A
- RCUS N/A
- Revenue Next Year
- OCFC $12.62
- RCUS $25.77
- P/E Ratio
- OCFC $10.01
- RCUS N/A
- Revenue Growth
- OCFC N/A
- RCUS 120.51
- 52 Week Low
- OCFC $14.03
- RCUS $6.50
- 52 Week High
- OCFC $21.87
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- OCFC 54.23
- RCUS 51.07
- Support Level
- OCFC $15.59
- RCUS $7.65
- Resistance Level
- OCFC $16.93
- RCUS $8.51
- Average True Range (ATR)
- OCFC 0.78
- RCUS 0.60
- MACD
- OCFC 0.18
- RCUS 0.19
- Stochastic Oscillator
- OCFC 83.71
- RCUS 94.78
About OCFC OceanFirst Financial Corp.
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.